Cipher is continually seeking to acquire and develop promising product candidates with the potential to transform the standard of care in dermatology. Our growing pipeline includes both late-stage products and earlier stage assets that address unmet medical needs.
Cipher has also acquired six pre-clinical compounds for the treatment of melanoma and other cancers. The clinical plan for these compounds has not yet been established.
b) Pruridexin is under review by European Medicines Agency.
c) Dermadexin has CE Mark in EU.
d) ASF-1096 was awarded orphan drug status in EU.
e) Dermadexin is under review by FDA as a 510-k.